mouse monoclonal anti tpp1 antibody Search Results


recombinant human tpp1 cerliponase alfa  (BioMarin Inc)
90
BioMarin Inc recombinant human tpp1 cerliponase alfa
Heidelberg SD-OCT RNFL analysis of a 9.5-year-old patient with late-infantile <t>CLN2</t> disease. PRNFL is significantly decreased in the global, temporal superior and temporal inferior pRNFL sectors.
Recombinant Human Tpp1 Cerliponase Alfa, supplied by BioMarin Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti+tpp1+antibody/mouse+anti+tpp1+monoclonal+antibody/pmc11571076-125-9-15
Average 90 stars, based on 1 article reviews
recombinant human tpp1 cerliponase alfa - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Heidelberg SD-OCT RNFL analysis of a 9.5-year-old patient with late-infantile CLN2 disease. PRNFL is significantly decreased in the global, temporal superior and temporal inferior pRNFL sectors.

Journal: Eye and Brain

Article Title: Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness – A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 Disease

doi: 10.2147/EB.S473408

Figure Lengend Snippet: Heidelberg SD-OCT RNFL analysis of a 9.5-year-old patient with late-infantile CLN2 disease. PRNFL is significantly decreased in the global, temporal superior and temporal inferior pRNFL sectors.

Article Snippet: Currently, intracerebroventricular (ICV) enzyme replacement therapy (ERT) with recombinant human TPP1 (rhTPP1) (cerliponase alfa, Brineura, BioMarin Pharmaceuticals, California, USA) is the only United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) approved treatment for CLN2 that has proven to decelerate the progression of motor and language function decline.

Techniques: